O1‐02‐04: BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER'S DISEASE (CREAD). (1st July 2006) - Lin, Helen; Ostrowitzki, Susanne; Sink, Kaycee M.; Millar, Laurie; Warren, Francis; Smith, Jillian; Schneider, Andres; Fuji, Reina N.; Quartino, Angelica; Mackey, Howard; Rabbia, Michael A.; Yule, Susan; et al.